What the Test Detects and What It Misses
The FDA has approved the first blood test that Abbott will sell as a colorectal cancer screening option, and the most important number in the announcement is the one describing what it does not find.
The test, SimpleScreen CRC, was developed by Freenome and approved on July 27 for adults aged 45 and older at average risk. It detects signals from cell-free DNA in a blood sample and requires only a routine blood draw. Abbott will commercialize it in the United States beginning this fall.
In the analysis supporting the commercial test, adjusted to match the U.S. Census, the test detected colorectal cancer with 81.1 percent sensitivity and showed 90.4 percent specificity for advanced colorectal neoplasia. In plain terms, it correctly identified roughly eight in ten cancers and returned a correct negative result for about nine in ten people without cancer or advanced precancerous lesions.
Its sensitivity for advanced precancerous lesions was 13.7 percent, rising to 30.7 percent for lesions with high-grade dysplasia. That limitation belongs here rather than at the end of the article, because it defines what the test can and cannot do.
Why the Precancer Number Matters Most
Colorectal cancer screening is unusual among cancer screening programs. It does not only find cancer earlier. Done well, it prevents cancer from developing at all.
Colonoscopy achieves that by locating and removing precancerous polyps before they can turn malignant. A test that detects fewer than one in seven advanced precancerous lesions is not doing that work. It is largely finding disease that has already become cancer, at a point when treatment is more effective than it would be later but the opportunity for prevention has passed.
The published PREEMPT CRC analysis makes this explicit. In that peer-reviewed report, sensitivity for advanced precancerous lesions was 12.5 percent, which did not meet the study's prespecified acceptance criterion. The test met its cancer detection goal and fell short on precancer detection, and readers should weigh both results rather than only the headline figure.
None of this makes the test useless. It makes it a different kind of tool, best understood as a way to catch cancers in people who would otherwise be screened by nothing at all.
Where It Fits in Current Screening Guidelines
The study behind the approval was substantial. PREEMPT CRC was a prospective, multicenter study conducted at more than 200 sites, enrolling over 48,000 asymptomatic average-risk adults aged 45 to 85 who were already scheduled for a screening colonoscopy. Results were published in JAMA, a peer-reviewed journal.
Current guidance still places other methods first. American Cancer Society recommendations favor stool-based tests and visual examinations such as colonoscopy, positioning blood-based tests for people unwilling or unable to complete the preferred options. The companies expect SimpleScreen CRC to be added to those guidelines by name, which has not yet happened.
The companies are also explicit about a point patients should not miss. A positive result means a signal was detected, not that cancer is present, and it "should be followed by diagnostic colonoscopy." The test is not a replacement for diagnostic colonoscopy, nor for surveillance colonoscopy in people at high risk.
Anyone who tests positive is therefore going to have a colonoscopy. The blood draw does not avoid the procedure; it changes who gets referred for one.
Coverage, Cost, and When It Arrives
The test is not yet available. Abbott has said commercialization begins this fall, and no launch date or list price has been announced.
Coverage is more settled than usual for a newly approved test. Earlier this year, the Centers for Medicare and Medicaid Services adopted performance-based standards qualifying biomarker-based colorectal cancer tests for Medicare coverage, and the companies say SimpleScreen CRC now meets those criteria. Medicare generally covers qualifying noninvasive biomarker screening tests every three years under defined conditions.
Commercial insurance is less predictable. Newly approved tests often face coverage delays, and patients should ask whether their plan covers it before assuming a screening test will be paid at no cost. A screening test that is covered without cost sharing can still generate bills if a positive result leads to a colonoscopy where a polyp is removed, since some plans process that as a diagnostic procedure. That is worth asking about in advance.
Despite the approval, the test will require a clinician referral. It is not a product patients can buy off a pharmacy shelf.
Who Should Consider It and Who Should Not
Up to 60 million Americans are overdue for recommended colorectal cancer screening, and colorectal cancer remains the second leading cause of cancer death in the United States. Anjee Davis, chief executive of the advocacy group Fight Colorectal Cancer, noted in the companies' announcement that "90% of colorectal cancer deaths are preventable."
The strongest case for this test is a person who has repeatedly declined colonoscopy and will not complete a stool-based test either. For that person, a blood draw during a routine visit is meaningfully better than no screening.
The weakest case is a person who is willing to have a colonoscopy or to complete a stool test. Choosing the blood test instead means accepting substantially worse detection of the precancerous lesions that screening exists to remove.
The test is not intended for people at high risk, including those with a personal or family history of colorectal cancer or polyps, inflammatory bowel disease, or relevant genetic syndromes, who need colonoscopy-based surveillance. It is also not a test for people with symptoms. Rectal bleeding, persistent changes in bowel habits, unexplained weight loss or abdominal pain warrant prompt clinical evaluation, not a screening test.
Nobody should cancel a scheduled colonoscopy in order to wait for this test. Anyone weighing options should raise them with a clinician who knows their history.
The confirmed fact is FDA approval of a blood-based screening test for average-risk adults 45 and older. The people it most concerns are adults who have declined other screening. The reasonable action is a conversation about which method someone will actually complete. The central uncertainty is whether a test that finds few precancerous lesions will reduce deaths as much as existing options. The next expected developments are the fall launch and formal guideline inclusion.
Frequently Asked Questions
What does this test do? It analyzes cell-free DNA in a blood sample to detect signals associated with colorectal cancer in average-risk adults aged 45 and older.
How accurate is it? It detected about 81 percent of colorectal cancers and 13.7 percent of advanced precancerous lesions, with about 90 percent specificity.
Does it replace colonoscopy? No. A positive result requires a follow-up diagnostic colonoscopy, and the test is not a substitute for diagnostic or surveillance colonoscopy.
Why does the precancer number matter? Colonoscopy prevents cancer by removing precancerous polyps. A test that finds few of them detects cancer rather than preventing it.
When can I get it and will insurance cover it? Abbott plans to launch it this fall. The companies say it meets Medicare coverage criteria. Commercial coverage varies, so ask your plan.
Who should not use it? People at high risk, those needing surveillance colonoscopy, and anyone with symptoms such as rectal bleeding or persistent bowel changes.
Is it available at pharmacies? No. It requires a clinician referral and a blood draw, not an over-the-counter purchase.
